Introgens gene drug demonstrates tumor growth control
... ...Houston and Austin, TX, October 25, 2001- Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today that results of preclinical studies in melanoma have been published in the October 2001 issue of International Journal of Cancer in a manuscript entitled Down-Regulated Melanoma Differentiation Associated Gene (MDA-7) Expression in Human Melanomas. The manuscripts authors include lead auth...Austin, TX, October 11, 2001- Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today that it has licensed a group of newly discovered and sequenced genes that appear to play a critical role in suppressing and preventing the development of lung and other cancers. This family of genes includes at least ten members. Discovery of these tumor suppressor genes represents a joint collaborative effor....Austin, TX, May 10, 2001- Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today the publication of its preclinical studies in the current issue of Molecular Medicine demonstrating the potent anti-tumor effects of INGN 241 (an adenoviral vector encoding the mda-7 gene) in three of the most prevalent human cancers, breast, lung and colorectal. . The study also demonstrates, for the first ti.... . . New Orleans, LA, May 23, 2000 - Introgen Therapeutics presented data from clinical studies on the safety, transfer and expression of RPR/INGN 201 (Adenoviral p53) in three Phase I clinical studies for the treatment of bronchioalveolar cell lung carcinoma (BAC), ovarian cancer and recurrent glioblastomas at the 36th American Society of Clinical Oncology (ASCO) Annual Meeting in New Orlea...Introgen Therapeutics reports progress in gene therapy studies at annual ASCO meeting
New Orleans, LA - May 21, 2000 - Introgen Therapeutics, Inc. today presented data from its clinical studies of adenoviral p53 gene therapy at the 36th American Society of Clinical Oncology (ASCO) Annual Meeting in New Orleans, Louisiana. Data presented showed promising Phase II interim results using a patented adenoviral p53 therapy in conjunction with radiation therapy for the treatment of non-...